Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.thyrocare.com | |
Market Cap | 2,487.71 Cr. | |
Enterprise Value(EV) | 2,459.24 Cr. | 2023-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 12.18 | Trailing Twelve Months Ending 2023-03 |
Price-Earning Ratio (PE) | 38.42 | Trailing Twelve Months Ending 2023-03 |
Industry PE | 49.44 | Trailing Twelve Months Ending 2023-03 |
Book Value / Share | 100.94 | Trailing Twelve Months Ending 2023-03 |
Price to Book Value | 4.64 | Calculated using Price: 468.10 |
Dividend Yield | 3.19 | Period Ending 2022-03 |
No. of Shares Subscribed | 5.29 Cr. | 52,930,043 Shares |
FaceValue | 10 | |
About Thyrocare Technologies Ltd. | ||
Thyrocare Technologies is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers cancer diagnosis and water testing through its brands Nueclear and Whaters, respectively. |
1 Day |
|
-0.99% |
1 Week |
|
-3.27% |
1 Month |
|
+1.56% |
3 Month |
|
-1.02% |
6 Month |
|
-24.45% |
1 Year |
|
-31.70% |
2 Year |
|
-56.27% |
5 Year |
|
-21.45% |
10 Year |
|
8 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 15.98 | 16.22 | 11.20 | 22.16 | 19.41 | 22.13 | 28.75 | 37.18 | |
Return on Capital Employed (%) | 24.57 | 25.66 | 21.05 | 33.93 | 31.36 | 35.14 | 38.51 | 48.24 | |
Return on Assets (%) | 13.41 | 14.09 | 10.20 | 20.59 | 17.93 | 18.73 | 22.43 | 30.87 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
Shh. Funds | 276 | 366 | 408 | 443 | 435 | 367 | 427 | 527 | 534 | |
Non Curr. Liab. | 9 | 10 | 9 | 10 | 14 | 21 | 18 | 10 | 8 | |
Curr. Liab. | 7 | 31 | 18 | 20 | 21 | 82 | 95 | 65 | 77 | |
Minority Int. | 36 | 1 | ||||||||
Equity & Liab. | 328 | 407 | 434 | 474 | 470 | 469 | 540 | 601 | 620 | |
Non Curr. Assets | 218 | 273 | 285 | 332 | 334 | 317 | 300 | 331 | 348 | |
Curr. Assets | 111 | 134 | 150 | 142 | 136 | 152 | 240 | 270 | 273 | |
Misc. Exp. not W/O | ||||||||||
Total Assets | 328 | 407 | 434 | 474 | 470 | 469 | 540 | 601 | 620 |
Particulars | 9 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. TTM |
Net Sales | 183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 527 | |
Other Income | 8 | 7 | 12 | 23 | 10 | 7 | 12 | 29 | 8 | |
Total Income | 191 | 248 | 317 | 380 | 413 | 441 | 507 | 618 | 535 | |
Total Expenditure | -110 | -147 | -189 | -212 | -249 | -261 | -323 | -354 | -407 | |
PBIDT | 81 | 101 | 128 | 168 | 164 | 180 | 184 | 264 | 128 | |
Interest | 0 | -1 | 0 | 0 | -1 | -2 | -1 | -2 | -2 | |
Depreciation | -13 | -18 | -18 | -20 | -26 | -32 | -30 | -34 | -39 | |
Taxation | -24 | -30 | -39 | -52 | -53 | -52 | -39 | -52 | -24 | |
Exceptional Items | -27 | -2 | -7 | |||||||
PAT | 44 | 52 | 43 | 93 | 85 | 88 | 113 | 176 | 63 | |
Minority Interest | 1 | 0 | ||||||||
Share Associate | 1 | 1 | 1 | |||||||
Other Related Items | 0 | -1 | 0 | |||||||
Consolidated Net Profit | 45 | 52 | 43 | 93 | 85 | 89 | 112 | 176 | 64 | |
Adjusted EPS | 9 | 10 | 8 | 17 | 16 | 17 | 21 | 33 | 12 |
Particulars | 8 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 34 | 68 | 90 | 107 | 100 | 168 | 115 | 113 | |
Cash Fr. Inv. | -18 | -18 | -42 | -43 | -12 | 1 | -49 | -24 | |
Cash Fr. Finan. | -23 | -45 | -49 | -64 | -94 | -165 | -62 | -89 | |
Net Change | -6 | 5 | 0 | 0 | -5 | 4 | 4 | 0 | |
Cash & Cash Eqvt | 5 | 10 | 10 | 10 | 5 | 9 | 13 | 14 |
Thu, 08 Jun 2023
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Nippon Life India Trustee Ltd |
Sat, 03 Jun 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Disclosure of information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - Meeting with Investors/Analysts |
Tue, 30 May 2023
Compliances-Reg.24(A)-Annual Secretarial Compliance Pursuant to Regulation 24A of the Listing Regulation read with SEBI circular no CIR/CFD/CMD1/27/2019 dated February 8 2019 BSE Notice No. 20230316-14 and NSE Circular Ref No: NSE/CML/2023/21 both dated March 16 2023 please find enclosed herewith Annual Secretarial Compliance Report for the financial year ended March 31 2023 issued by V Suresh Associates Secretarial Auditors of the Company. |
Fri, 09 Jun 2023 |
|
|
|
S Closing Below Previous Low for 2 Days |
S Making Lower Lows for 2 Days |